Evidence map›Paper›PMID 42332237›Full record

ArticleJournal of imaging informatics in medicine2026

Computerized Classification Method for Glioma Molecular Subtypes on Brain MR Images Using SAM-Med3D with Low-Rank Adaptation.

Akiyoshi Hizukuri

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of imaging informatics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Akiyoshi HizukuriYokohama City University, 22-2 Seto, Kanazawa-Ku, Yokohama, Kanagawa, Japan. hizukuri.aki.jx@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0001-5963-3900

Funding

Japan Society for the Promotion of Science 23K11909
6 · The paper itself

Abstract

It is important to identify the molecular subtypes of gliomas to determine appropriate management strategies for patients. However, genetic testing requires tumor tissue obtained through surgical resection, which imposes a considerable burden on patients. Hence, we propose a computerized molecular subtype classification method based on brain magnetic resonance (MR) images using a pretrained 3D foundation model. Our dataset consists of T1-weighted (T1w), T2-weighted (T2w), fluid-attenuated inversion recovery (FLAIR), and contrast-enhanced T1-weighted (T1ce) brain MR images from the BraTS2020 dataset. The proposed model was trained and evaluated using this dataset, which comprises data from 148 patients for training and 70 patients for testing. Our proposed SAM-Med3D-based multi-modal network incorporates four modality-specific 3D image encoders for the T1w, T2w, FLAIR, and T1ce images. Each encoder is efficiently adapted using low-rank adaptation, and a classification head is introduced for glioma molecular subtype classification. Multi-modal MR images are independently processed by the modality-specific encoders to extract image embeddings. These embeddings, together with the prompt embeddings generated by the 3D prompt encoder, are integrated by the 3D mask decoder to produce tumor segmentation outputs. The shared encoder features are concatenated and sent to the classification head for glioma molecular subtype classification. The area under the curve for the proposed method was 0.931, exceeding that of the conventional networks such as SGPNet (0.827), MA-MTLN (0.902), and MTTU-Net (0.910). This result indicates that the proposed SAM-Med3D-based network could enable effective and accurate molecular subtype classification using multi-modal brain MR images.

Indexed as

Brain MR imageGlioma molecular subtypesLow-rank adaptationSAM-Med3DTransfer learning

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.